A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219)

• Status: Completed
• Trial end date: 2004-03-15
• Target enrollment: 0
• Participant gender: Female

Summary

This study is to assess the safety and tolerability of MK0217 being evaluated to treat women with postmenopausal osteoporosis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Alendronate

Criteria

Inclusion Criteria:

• Women with postmenopausal osteoporosis

Exclusion Criteria:

• High risk for fractures

• Esophageal abnormalities

• Upper gastrointestinal symptoms that are not relieved with medication

• Metabolic bone disease (example - vitamin D deficiency)

• Medications that would affect the breakdown or build-up of bone